Showing 1801-1810 of 3223 results for "".
- Alkeus Pharmaceuticals Announces Positive Results from SAGA Study of Gildeuretinol Acetate in GA Patientshttps://modernod.com/news/alkeus-pharmaceuticals-announces-positive-results-from-saga-study-of-gildeuretinol-acetate-in-ga-patients-3/2482445/Alkeus Pharmaceuticals announced results from the SAGA study, a phase 3 clinical trial of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study demonstrated a reduction in the growth rate of GA lesions by
- Alcon Unveils SMARTCataract DX and Ngenuity 1.5 at ESCRShttps://modernod.com/news/alcon-unveils-innovations-at-escrs-including-smartcataract-dx-and-ngenuity-15/2482433/Alcon is introducing new technologies at the European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting aimed at improving efficiency and outcomes in cataract surgery. Among the announcements are the unveiling of the SMARTCataract DX digital planning solution and the upgraded Nge
- Alcon Announces New Cataract Surgery Outcomes Data, Hosts Educational Program at ESCRShttps://modernod.com/news/alcon-announces-new-cataract-surgery-outcomes-data-hosts-educational-program-at-escrs/2482426/Alcon is set to unveil new scientific data at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Barcelona, from September 6-10, 2024. The company will showcase its surgical ophthalmic products and equipment, highlighting innovations designed to optimize
- Ocumension Therapeutics Secures Deal with Alcon to Expand Dry Eye Treatment Portfolio in Chinahttps://modernod.com/news/ocumension-therapeutics-secures-deal-with-alcon-to-expand-dry-eye-treatment-portfolio-in-china/2482395/China-based ophthalmic pharmaceutical company Ocumension Therapeutics announced an agreement with Alcon under which OcuMension will acquire or secure commercialization rights in China to a portfolio of Alcon’s dry eye treatments and procedural drops, including establishe
- Aldeyra Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalaphttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reproxalap/2482391/Aldeyra Therapeutics announced the primary endpoint has been achieved in its phase 3 trial of investigational reproxalap for dry eye disease. In the randomized, double-masked, vehicle-controlled dry eye chamber clinical trial, reproxalap 0.25% was statistic
- Lensar's ALLY Adaptive Cataract Treatment System Approved in Europehttps://modernod.com/news/lensars-ally-adaptive-cataract-treatment-system-approved-in-europe/2482390/Lensar announced that the ALLY Adaptive Cataract Treatment System is now commercially available in Europe after receiving certification under the European Union’s Medical Device Regulation (MDR). Lensar is commercializing ALLY through its di
- OcuCell Announces Funding from AltruVision and New Board Appointmentshttps://modernod.com/news/ocucell-announces-funding-from-altruvision-and-leadership-changes/2482354/OcuCell announced it has received funding from AltruVision to enable OcuCell to continue advancing its Endo-Tek and Epi-Tek ocular cell therapy treatments. Financial terms of the funding were not disclosed. Established in 1957, AltruVision recovers over 1,500 eye don
- Alcon Completes Acquisition of Belkin Visionhttps://modernod.com/news/alcon-completes-acquisition-of-belkin-vision/2482338/Alcon announced the closing of its acquisition of Belkin Vision, which was initially reported in May 2024. The acquisition involved a total upfront
- FDA Clears Alcon's Unity Vitreoretinal-Cataract System and Standalone Cataract Systemhttps://modernod.com/news/fda-clears-alcons-unity-vitreoretinal-cataract-system-and-unity-standalone-cataract-system/2482329/Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received FDA 510(k) clearance. The new devices are the first to be introduced from Alcon’s Unity portfolio and represent Alcon's next generation of e
- Aurion Biotech Completes Enrollment In Phase 1/2 Clinical Trial of Allogeneic Cell Therapy Candidatehttps://modernod.com/news/aurion-biotech-completes-enrollment-in-phase-12-clinical-trial-of-allogeneic-cell-therapy-candidate/2482306/Aurion Biotech announced that it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. “Aurion Biotech is delighted that both enrollm